| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2003.10.042 |
| P698 | PubMed publication ID | 15837242 |
| P2093 | author name string | Goldman GS | |
| P2860 | cites work | The incidence of herpes zoster | Q28109329 |
| Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study | Q28111909 | ||
| Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox | Q28111950 | ||
| Prevalence of antibodies to four herpesviruses among adults with glioma and controls | Q28205730 | ||
| Varicella disease after introduction of varicella vaccine in the United States, 1995-2000 | Q28217599 | ||
| Incidence of Herpes Zoster in Pediatricians and History of Reexposure to Varicella-zoster Virus in Patients with Herpes Zoster | Q34298536 | ||
| Economic evaluations of varicella vaccination programmes: a review of the literature | Q35026965 | ||
| American grandparents providing extensive child care to their grandchildren: prevalence and profile | Q40710554 | ||
| Modelling the impact of immunization on the epidemiology of varicella zoster virus | Q40722872 | ||
| Vaccine safety: current and future challenges | Q40849894 | ||
| Epidemiologic effects of varicella vaccination | Q41150975 | ||
| The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales | Q43439315 | ||
| Immunologic Evidence of Reinfection with Varicella-Zoster Virus | Q43820803 | ||
| Instituting a routine varicella vaccination program in Canada: an economic evaluation | Q44470952 | ||
| Do the benefits of varicella vaccination outweigh the long-term risks? A decision-analytic model for policymakers and pediatricians | Q44739941 | ||
| Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage | Q44970591 | ||
| Varicella susceptibility and incidence of herpes zoster among children and adolescents in a community under active surveillance | Q46063529 | ||
| Immunization to reduce the frequency and severity of herpes zoster and its complications | Q46138173 | ||
| The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. | Q50651133 | ||
| The cost-effectiveness of varicella vaccine programs for Australia. | Q50652609 | ||
| Costs And Benefits Of Routine Varicella Vaccination In German Children | Q57515370 | ||
| Childhood vaccination against chickenpox: an analysis of benefits and costs | Q72504606 | ||
| An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients | Q72552703 | ||
| Economic evaluation of vaccination programs: the impact of herd-immunity | Q72990042 | ||
| Lasting immunity to varicella in doctors study (L.I.V.I.D. study) | Q74562023 | ||
| The cost-effectiveness of varicella vaccination in Canada | Q77526064 | ||
| Varicella vaccine and shingles | Q78019415 | ||
| The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France | Q78164010 | ||
| The cost-effectiveness of routine childhood varicella vaccination in Germany | Q78862020 | ||
| P433 | issue | 25 | |
| P921 | main subject | cost–benefit analysis | Q942582 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 3349-3355 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology | |
| P478 | volume | 23 |
| Q26777698 | Advances in pediatrics in 2014: current practices and challenges in allergy, gastroenterology, infectious diseases, neonatology, nutrition, oncology and respiratory tract illnesses |
| Q79765860 | Assessing the introduction of universal varicella vaccination in the Netherlands |
| Q51138672 | Cost effectiveness of herpes zoster vaccine in Canada. |
| Q51871886 | Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. |
| Q37135445 | Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination |
| Q79965616 | Economic evaluation of varicella vaccination in Spain: results from a dynamic model |
| Q31130703 | Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination |
| Q37011064 | Herpes zoster vaccination |
| Q33956779 | Herpes zoster vaccine for the elderly: boosting immunity |
| Q24624044 | Immune modulation during latent herpesvirus infection |
| Q46174982 | Modelling the impact of varicella vaccination on varicella and zoster. |
| Q36642986 | Prevention of shingles: safety and efficacy of live zoster vaccine |
| Q26863614 | Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data |
| Q36445564 | Successes and remaining challenges after 10 years of varicella vaccination in the USA. |
| Q54704357 | Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. |
| Q43566977 | Uptake of varicella vaccine--a cross sectional survey of parental attitudes to nationally recommended but unfunded varicella immunisation. |
| Q36548655 | Zoster vaccine live (Oka/Merck). |
Search more.